The licensing deal for BAFF/APRIL inhibitor telitacicept, which also includes regulatory and commercial milestones exceeding ...

IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published ...

In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant ...

PureTech Heath founded clinical-stage biotech Vor Bio has entered into an exclusive license agreement with RemeGen to develop ...

Review the current Graphene Manufacturing Group Ltd (GMG:XTSX) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if GMG is the best investment for you.

Alexion to present seven abstracts, including four oral presentations, from its leading rare neurology portfolio at EAN 2025: Cambridge, UK Monday, June 23, 2025, 13:00 Hrs [IST] ...

ABOUT GENERALIZED MYASTHENIA GRAVIS (gMG)Myasthenia gravis (MG) is an autoantibody disease in which the immune system mistakenly makes antibodies (e.g., anti-acetylcholine receptor [AChR], anti ...

Johnson & Johnson (NYSE: JNJ) today announced new data from an indirect treatment comparison (ITC) that showed consistent and sustained disease control with IMAAVY™ (nipocalimab-aahu) versus other ...

The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a ...